<SEC-DOCUMENT>0001628280-17-004500.txt : 20170428
<SEC-HEADER>0001628280-17-004500.hdr.sgml : 20170428
<ACCEPTANCE-DATETIME>20170428170004
ACCESSION NUMBER:		0001628280-17-004500
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		4
CONFORMED PERIOD OF REPORT:	20170428
ITEM INFORMATION:		Other Events
FILED AS OF DATE:		20170428
DATE AS OF CHANGE:		20170428

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			CUMBERLAND PHARMACEUTICALS INC
		CENTRAL INDEX KEY:			0001087294
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-33637
		FILM NUMBER:		17796703

	BUSINESS ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE,
		STATE:			TN
		ZIP:			37203
		BUSINESS PHONE:		615-255-0068

	MAIL ADDRESS:	
		STREET 1:		2525 WEST END AVENUE
		STREET 2:		SUITE 950
		CITY:			NASHVILLE
		STATE:			TN
		ZIP:			37203
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>a8k-kristalosecoxpromotion.htm
<DESCRIPTION>8-K - KRISTALOSE CO-PROMOTION AGREEMENT
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Document</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s10f772c8307848d6af8198bca80a7cc5"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">UNITED STATES</font></div><div style="line-height:120%;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;">SECURITIES AND EXCHANGE COMMISSION</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">WASHINGTON, D.C. 20549</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:18pt;"><font style="font-family:inherit;font-size:18pt;">FORM 8-K</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">CURRENT REPORT</font></div><div style="line-height:120%;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:93.5546875%;border-collapse:collapse;text-align:left;"><tr><td colspan="2"></td></tr><tr><td style="width:52%;"></td><td style="width:48%;"></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Date of Report (Date of Earliest Event Reported):                &#160;                        April 28, 2017 (April 26, 2017)</font></div></td></tr></table></div></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:24pt;"><font style="font-family:inherit;font-size:24pt;">Cumberland Pharmaceuticals Inc.</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">__________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Exact name of registrant as specified in its charter)</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#32;&#32;&#32;&#32;&#32;&#32;</font><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;margin-left:auto;margin-right:auto;width:98.046875%;border-collapse:collapse;text-align:left;"><tr><td colspan="4"></td></tr><tr><td style="width:0%;"></td><td style="width:39%;"></td><td style="width:28%;"></td><td style="width:33%;"></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">001-33637</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;text-decoration:underline;">62-1765329</font></div></td></tr><tr><td><font>&#160;</font></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(State or other jurisdiction of incorporation)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Commission File Number)</font></div></td><td rowspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(I.R.S. Employer Identification No.)</font></div></td></tr><tr><td><font>&#160;</font></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">2525 West End Avenue, Suite 950, Nashville, Tennessee</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">37203</font></div></td></tr><tr><td><font>&#160;</font></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Address of principal executive offices)</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">(Zip Code)</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td><font>&#160;</font></td><td colspan="3" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Registrant's telephone number, including area code:  (615) 255-0068</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Not Applicable</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">____________________________________________</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Former name or former address, if changed since last report</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">[&#160;&#160;]&#160;&#160;Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">Item 8.01 Other Events</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:12pt;"><font style="font-family:inherit;font-size:10pt;">On April 26, 2017, Cumberland Pharmaceuticals Inc. (the "Company") issued a press release announcing that the Company and Poly Pharmaceuticals Inc. have entered into a co-promotion partnership for Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174; </sup></font><font style="font-family:inherit;font-size:10pt;">within the United States. Poly&#8217;s sales force will more than double the number of nationwide physicians called upon in support of the product.  A copy of the press release is furnished as Exhibit 99.1.</font></div><div style="line-height:120%;padding-bottom:10px;text-align:justify;text-indent:24px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-weight:bold;">SIGNATURES</font></div><div style="line-height:120%;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</font></div><div style="line-height:120%;font-size:10pt;"><div style="padding-left:0px;text-indent:0px;line-height:normal;padding-top:10px;"><table cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:94.3359375%;border-collapse:collapse;text-align:left;"><tr><td colspan="3"></td></tr><tr><td style="width:7%;"></td><td style="width:61%;"></td><td style="width:32%;"></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td colspan="2" style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;height:20px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">Cumberland Pharmaceuticals Inc.</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">April 28, 2017</font></div></td><td style="vertical-align:bottom;border-bottom:1px solid #000000;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">By: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Name: Michael Bonner</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">Title: Chief Financial Officer</font></div></td></tr><tr><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="overflow:hidden;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td><td style="vertical-align:bottom;padding-left:2px;padding-top:2px;padding-bottom:2px;padding-right:2px;"><div style="text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;">&#160;</font></div></td></tr></table></div></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;text-align:left;text-indent:48px;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;font-style:italic;">&#160;&#160;&#160;&#160;</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>pressrelease-coxpromotiona.htm
<DESCRIPTION>EXHIBIT 99.1 - PRESS RELEASE CO-PROMOTION
<TEXT>
<!DOCTYPE html PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
	<head>
		<!-- Document created using Wdesk 1 -->
		<!-- Copyright 2017 Workiva -->
		<title>Exhibit</title>
	</head>
	<body style="font-family:Times New Roman;font-size:10pt;">
<div><a name="s1b520b48cfe64a129280488ca6f3a3f3"></a></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:120%;text-align:left;font-size:11pt;"><img src="cumberlanda04.gif" alt="cumberlanda04.gif" style="font-size:11pt;font-weight:bold;height:73px;width:321px;"><font style="font-family:inherit;font-size:11pt;font-weight:bold;">&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;&#32;</font><img src="polu.jpg" alt="polu.jpg" style="font-size:11pt;font-weight:bold;height:70px;width:300px;"></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">NEW KRISTALOSE</font><font style="font-family:inherit;font-size:13pt;font-weight:bold;"><sup style="vertical-align:top;line-height:120%;font-size:pt">&#174; </sup></font><font style="font-family:inherit;font-size:13pt;font-weight:bold;">GROWTH DRIVER ESTABLISHED</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:center;font-size:13pt;"><font style="font-family:inherit;font-size:13pt;font-weight:bold;">THROUGH CO-PROMOTION AGREEMENT</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:16px;padding-top:8px;text-align:center;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;">&#32;Poly Pharmaceuticals will significantly expand national physician coverage</font></div><div style="line-height:120%;text-align:left;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Nashville, Tenn, April 26, 2017 - Cumberland Pharmaceuticals (NASDAQ: CPIX), </font><font style="font-family:inherit;font-size:12pt;">a U.S. specialty pharmaceutical company and </font><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Poly Pharmaceuticals Inc.</font><font style="font-family:inherit;font-size:12pt;">, a privately-held U.S. specialty pharmaceutical company, have entered into a co-promotion partnership for Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;within the United States.  Poly&#8217;s sales force will more than double the number of nationwide physicians called upon in support of the product.</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kristalose is a unique, dry powder, crystalline formulation of lactulose that is designed to enhance patient compliance during treatment of acute and chronic constipation. It is the only prescription laxative available in pre-measured powder packets, making it convenient and easily portable.</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Poly and Cumberland&#8217;s multi-year co-promotion partnership will expand current promotional support for Kristalose across the United States. Poly&#8217;s sales organization will promote the features of Kristalose, provide amplified sales promotion, and increased communication to thousands of additional medical professionals. Cumberland will continue to manage national marketing, distribution, regulatory, and medical support for the brand.</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Under the terms of the agreement, Cumberland shall provide co-promotional payments to Poly based on the incremental prescriptions generated by Poly&#8217;s sales organization.  Poly projects their efforts will significantly grow the sales of Kristalose during the multi-year agreement term. Cumberland will provide sales training and promotional materials for Poly&#8217;s sales professionals who will focus on new physician segments in support of the brand.</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">&#8220;Kristalose is an outstanding product with considerable untapped potential,&#8221; said Chase Williams, President of Poly Pharmaceuticals, Inc. &#8220;It is an excellent fit for our sales force and the physicians they support.&#8221;</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">"We welcome Poly as a co-promotional partner and believe this collaboration will provide a new growth driver for Kristalose, our largest selling product,&#8221; said A.J. Kazimi, Chief Executive Officer of Cumberland </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Pharmaceuticals.  &#8220;We are excited to expand the number of patients that will benefit from Kristalose, given its strong and proven track record of enhancing patient care.&#8221;</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Kristalose</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Kristalose is the only branded prescription laxative product that features the established safety and efficacy of lactulose, with the convenience of a pre-measured powder dose. Kristalose dissolves quickly in 4 oz. of water, offering patients a virtually tasteless, grit-free and essentially calorie-free alternative to lactulose syrups. There are no age limitations or length of use restrictions for Kristalose and it is the only osmotic prescription laxative still sampled to physicians. For full prescribing information, including boxed warning, visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.kristalose.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Poly Pharmaceuticals</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Poly Pharmaceuticals, Inc. is a privately-held specialty pharmaceutical company that is dedicated to developing a portfolio of innovative, safe, and cost effective medications for patients and caregivers. Poly currently markets a broad range of health care products for conditions such as cough, cold, allergy, sinusitis, pain relief, and urological health. The company was founded in 1980 by a group of pharmacists focused on developing and marketing pharmaceutical products. Poly continues to invest in recruiting talented sales professionals to market their specialty products throughout the United States. Find more information at www.polypharm.net.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">About Cumberland Pharmaceuticals</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on acquisition, development, and commercialization of high-quality products that improve the quality of care for patients. The Company has a diverse product portfolio with a focus in the areas of hospital acute care and gastroenterology. </font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland's marketed products include Acetadote</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(acetylcysteine) Injection for the treatment of acetaminophen poisoning, Caldolor</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, Kristalose</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(lactulose) for Oral Solution, a prescription laxative, Vaprisol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(conivaptan) Injection, for the treatment of hyponatremia, Omeclamox-Pak</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;for the treatment of H. pylori and duodenal ulcer disease, and Ethyol</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(amifostine) for Injection, for use by oncology patients. </font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland is also dedicated to developing innovative products that address unmet medical needs. The Company&#8217;s product candidates in clinical development include: Hepatoren</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ifetroban) Injection for the treatment of hepatorenal syndrome, Boxaban</font><font style="font-family:inherit;font-size:12pt;"><sup style="vertical-align:top;line-height:120%;font-size:8pt">&#174;</sup></font><font style="font-family:inherit;font-size:12pt;">&#32;(ifetroban) Oral Capsule for patients suffering from aspirin exacerbated respiratory disease, Vasculan&#8482; (ifetroban) Oral Capsule for the treatment of systemic sclerosis, and Portaban&#8482;, for the treatment of portal hypertension. </font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">For more information on Cumberland Pharmaceuticals Inc., and its products, please visit </font><font style="font-family:inherit;font-size:12pt;color:#0000ff;text-decoration:underline;">www.cumberlandpharma.com</font><font style="font-family:inherit;font-size:12pt;">.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;text-decoration:underline;">Important Note Regarding Forward Looking Statements</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">This press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland&#8217;s current views on future events based on what it believes are reasonable assumptions.  No assurance can be given that these events will occur.  </font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">As with any business, all phases of Cumberland&#8217;s operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland&#8217;s results of operations.  </font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">These factors include market conditions, competition, an inability of manufacturers to produce Cumberland&#8217;s products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company&#8217;s most recent Form 10-K and subsequent 10-Q&#8217;s as filed with the SEC.  There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects.  Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof.  The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.  </font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">SOURCE: Cumberland Pharmaceuticals Inc. and Poly Pharmaceuticals, Inc.</font></div><div style="line-height:174%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><hr style="page-break-after:always"><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div><div><br></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:center;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-weight:bold;">Contact Details</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">Poly Pharmaceuticals Incorporated</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: 1-800-882-1041</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Email: jpresley@polypharm.net</font></div><div style="line-height:174%;padding-bottom:13px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;font-style:italic;font-weight:bold;text-decoration:underline;">Cumberland Pharmaceuticals</font><font style="font-family:inherit;font-size:12pt;">Investor Contact:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Erin Smith</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Cumberland Pharmaceuticals</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: 615-255-0068</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">investors@cumberlandpharma.com</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Media Contact:</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Rebecca Kirkham</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Lovell Communications</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">Phone: 615-297-7766</font></div><div style="line-height:120%;padding-bottom:8px;padding-top:8px;text-align:justify;font-size:12pt;"><font style="font-family:inherit;font-size:12pt;">rebecca@lovell.com</font></div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div><div><br></div><div><div style="line-height:120%;font-size:10pt;"><font style="font-family:inherit;font-size:10pt;"><br></font></div></div>	</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>cumberlanda04.gif
<TEXT>
begin 644 cumberlanda04.gif
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M.N0GG3[<XBNI?IO?*;G>*7.FMVZ[2K)#"3OK:/%-%8/E)GF=9YY5![(//C0
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M)R.J$RZ:!BN_@A.7I=PUV7G!5[(O(ZY(JV7*/+*E.&)<Z'2B0U-6/LD'UG6
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ME2^9>,>YLYK0/  (_MQN &PB]#LJV-LD#!AXQ2].C2F8) 0]X-P!0D"2+/M
M ]"KH (.,(4Y/[E3J6ASM:O]9C=S8!I0U\<!R! MEP2!'P8X1=;W88!]<-WK
M!A  UT\A]GW3!0("$$ ">J#3#9!= %/J']K3SH/(A*0  @B[ #8@K#&D_>M>
M!WS7 Y_U1@5;*P7 >M?#/OC&@WT?9!\55_ ^=LCO(^^6)_SE3\%WM?0C5 (
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M *<P!H!P@W"7+X82@R@G@>*',"'A=_Q7$L7(%6C3D0^0BA+H!=/A!=+H %0
M!!L@#S"Y0R+Q "-##=FX$HC&3%<(9VYV;>C89J3@?>U("M?V ZE -"#D$:&8
M #18$O(0*@G  PO&A*X'DB6Q 7I'>PPR=U20B!<80#R0=QK0@ !W*LSXBE59
M$@[@>I6(%?48<<T!')0G?R$1E-JQ?TD( "9)D=%E7^I"@@$)D )0B?_"%7;)
M=8E9>+ZX-6/0=7$7;5Q!E*=PF"5!B ; #[37#\='#1MP  6 E.1!*&CA  A@
M#S4B%Y9"4.)PCLK9_Y73\'0_ '7>]V8'\ -30%,R-649Z'HT^(L>P3G/-Q(
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MRZ&WXV[SEVKWGZV7[.2;TWT]>R;QRST/=JXG]*'' )\HB&6=*IM1'2R%"E,
M =2B:VKA7_E9AO(&WM %$EBN%QC2 Y\#!+ZD"PCP^(Y?;KXD?%Q/W%3@2XS/
M^)#_^)D_!L*7V#JM+1I@W;$Q!4#  PB D2%!;H_?^K[T^)B/^9#*GXUJ;K'O
M^IH_^0APNA@HB:=;&H]S'4M9;@B0_Y.2,SV1K_F=KRV;+]A0K"V3?K2M<:SF
M9JE^6FY 8/Q0@C:2" 08^+JVS_FWO_N0FL8M<1I+3B^BG H'H/?*3>I_;QS
MHAP;7HD6/Q4$0)G]X"WRD/\  4#@0$ #"0P$((^ / " Y#'LQ_#A080 &"$\
M2$"C0(H .GH$T.\C( (.*X)LN#!A0I42/3(\61 AR882):ITJ#$CQ9$?*_H$
M29.CP((163+,Z=*H09+R9)ZT")4CPQ "+W+4.=2@5)TPGP;5^/!H2JDH*7X]
MV?%?60@^?$Q!=4"<@@,^R*#EV,^C7JA @7+5BI OPJME#1LN_/?P8<50\2+>
MNEARP\F3@?]>)#!8H&:,E3V;1=DY=.3&5@5++OS9LE[,G-=2!JD74"H?J%)-
MZ75 @00.=%-M2!TS<$C'FP_VN\IYZ-72!(>K3@N=^&:HA8.;!KVX^4F&VSV+
MI,YX*,_GURT_ER[9+W;OTL]B-SSXM50R4VJ+DZM _P\.I*9Q^.$ VNYB9#N9
MOE(LL[S**LJYT:#22SFIF$LONZ@>) H]P#*L3$*0*-2PK(] 5/"S$B-3;S)&
M^#J0P\8Z LI#K?1Z#\.?M&H.1-,HFH^\@7P0![>Y])/@!_XXF";)$:;11Q\
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M'QO'  0!*/%H&.,E/<S'QU^^#B$%2$ "#C C+T23"FD+S10$D !J.$N634S
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EENT,R5'!1LVO-'5DG#8]));2UFF4$%Y62XV/G4S60/F'@   .P$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>polu.jpg
<TEXT>
begin 644 polu.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" ": H,# 2(  A$! Q$!_\0
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M1_:&-_Y_R_\  G_F'U+"_P#/J/W+_(\4_P"&//@[_P!"9;?^!$__ ,77RO\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:ROEFM[FW\ZW;$"$;@05X/3-? MQ_J3_ +X_]"6OV(T*-6T73&8!BMM'@_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _&-?NK3^:8OW5I_-?T*
M?CA#<?ZD_P"^/_0EK]C/#_\ R ]-_P"O:/\ ] %?CG<?ZD_[X_\ 0EK]C/#_
M /R ]-_Z]H__ $ 5^?<7?#0_[>_0^NX=^*M_V[^IIT445^=GVH4444 %?#?_
M  42_P"1C\#?]>]W_-*^Y*^&_P#@HE_R,?@;_KWN_P":5])P[_R,8>DOR9X>
M=?[C/Y?FCY*YHYHYHYK]A/S@^R?^"='WOB#]-/\ _;FOM"OB_P#X)T?>^(/T
MT_\ ]N:^T*_&^(/^1E5^7_I*/TO*/]RI_/\ -A117FGC;]H[X6?#G7I-#\5?
M$'PYX<UB-%E>QU34XK>95894E6(.".:^>/8/2Z*\:_X;,^!'_17_  7_ .#N
MW_\ BJV?"7[2GPG\?:LFF>'/B5X5UG4I/N6=GK$$DS_[J!\G\* /3**** "B
MBB@ HJ&69+>-Y';;&H)9FZ "O,?"_P"U!\(O&OB"ST/P_P#$KPOK6L7C>7;6
M-AJL,TTK $X558DG H ]4HHHH **** "BBO-/&W[1WPL^'.O2:'XJ^(/ASPY
MK$:+*]CJFIQ6\RJPRI*L0<$<T >ET5XU_P -F? C_HK_ (+_ /!W;_\ Q5;/
MA+]I3X3^/M633/#GQ*\*ZSJ4GW+.SUB"29_]U ^3^% 'IE%%>5^*/VH/A%X*
M\07FA^(/B5X7T76+-O+N;&_U6&&:)B <,K,"#@T >J45#%,EQ&DB-NC8 JR]
M"#4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 445#+,EO&\CMMC4$LS= !0!-17E?A?]J#X1>-?$%GH?A_
MXE>%]:UB\;R[:QL-5AFFE8 G"JK$DX%>J4 %%%% !1110 4444 %%<-\0OC3
MX"^$LEC%XT\8:+X5>^#M;+J][';F94V[BN\C.-RY^M:_@OQYX<^(V@Q:YX5U
MS3_$.C2,R)?Z;<K/"S*V& 921D$<T =%1110 4444 %%%% !1110!^,:_=6G
M\TQ?NK3^:_H4_'"&X_U)_P!\?^A+7[&>'_\ D!Z;_P!>T?\ Z *_'.X_U)_W
MQ_Z$M?L9X?\ ^0'IO_7M'_Z *_/N+OAH?]O?H?7<._%6_P"W?U-.BBBOSL^U
M"BBB@ KX;_X*)?\ (Q>!O^N%W_-*^Y*^&_\ @HE_R,7@;_KA=_S2OI.'?^1C
M#TE^3/#SK_<9_+\T?)7-'-'-'-?L)^<'V3_P3H^]\0?II_\ [<U]H5\7_P#!
M.C[WQ!^FG_\ MS7VA7XWQ!_R,JOR_P#24?I>4?[E3^?YL*_"7_@K=_R>=KG_
M &"K#_T37[M5^$O_  5N_P"3SM<_[!5A_P"B:^>/8.M^ _\ P2:UWXZ?"'PQ
MX\M?B'IVDP:Y;?:DL9=-DE:)=[+@L)!G[OI7 ?M6?\$W?B!^RWX3D\72ZIIW
MBOPG!)%#<WMDK0S6K2-M4R1/GY2Q50RLW+#.*_1_]AW]HSX4>$/V3?AGI&N?
M$[P9HNJVNF[+BQU#Q!:P3Q-YKG:Z/(&4_45PG_!1S]M;X5S_ +.GB3P/X6\6
MZ/XS\0^)(X[2*/0[M+R&WC$B/)+))&2@PJX4;LECTP&H YO_ ()(_M<>(_B.
MNL?"KQAJ=QK5YI5E_:.CZA>2-)-]G5U22!W.2VTR(4R<XW+T48_2ROQ9_P""
M,?@_4-6_:/\ $/B&*,_V7H^@217$V>!+/+&(D_X$(Y3_ , KUG_@IW^WQXD\
M(^+KSX0_#?59-#FLXE_M_6K1BMSODC#"VBD_@ 1E+,IW9.W*[6R ?IO?^*-&
MTJ;R;W5K&TGQGR[BY1&_(D5H1R)<1JZ,'C89##D$&OQ$^&'_  2E^,OQF\%Q
M>--7UG2/#EUJ\7VRVM?$$T[WLY?)5Y]J-Y>[Y3R6;YN5!XKB?"?Q:^.'_!.'
MXQGPS?7-PEK9NLE[X:N+DRZ;J%NQ)WPGD)NRQ$B ,#]X?>2@#]Y]?_Y 6I?]
M>TG_ * :_GT_X)U_\GJ?"O\ [",O_I-+7[P^$OB%I/Q6^$=CXOT.1IM)UK2O
MMUL7&'57CSM8=F4\'WK\'O\ @G7_ ,GJ?"O_ +",O_I-+0!_0W17X<?\%/O"
M?BKX,_M/:I>:?KFK66@>*XAK-E'#>2I''(QV7$8 ;&?-5GZ#B5:_6']D3XM#
MXW?LW^ ?%SS_ &B^NM-CM[]]I&;N$>5.<'UD1C]#0![-17X2_P#!0KXY>(OB
ME^V-XAT;PIJ^I"VTJ:#PS8VVFW4B>?-&2)!A2 6,\DJU^S?P-^'+?";X0>$O
M",MU)?76E6$4-S=2,6::?&Z60DY^](6- '?U^$O_  5N_P"3SM<_[!5A_P"B
M:_=JOPE_X*W?\GG:Y_V"K#_T30!UOP'_ ."36N_'3X0^&/'EK\0].TF#7+;[
M4EC+ILDK1+O9<%A(,_=]*X#]JS_@F[\0/V6_"<GBZ75-.\5^$X)(H;F]LE:&
M:U:1MJF2)\_*6*J&5FY89Q7Z/_L._M&?"CPA^R;\,](USXG>#-%U6UTW9<6.
MH>(+6">)O-<[71Y RGZBN$_X*.?MK?"N?]G3Q)X'\+>+='\9^(?$D<=I%'H=
MVEY#;QB1'DEDDC)085<*-V2QZ8#4 <W_ ,$D?VN/$?Q'76/A5XPU.XUJ\TJR
M_M'1]0O)&DF^SJZI) [G);:9$*9.<;EZ*,?"'_!13_D]3XJ?]A&+_P!)HJ]U
M_P"",?@_4-6_:/\ $/B&*,_V7H^@217$V>!+/+&(D_X$(Y3_ , KPK_@HI_R
M>I\5/^PC%_Z314 ?O_I^IVNE^&=/N+VZAM(!;1 R3R!$R5'<XK0T_4[35K<3
MV5U!>0YQYD$@=<CMD5^0/BK]D7]IW]O+2K+XD:UJ>A^']!OH$GT'PYJVISQK
M!:;/W31Q1PNH+*<[W(9MV3@8KY4^'_Q$^(_[#_QXNEADN-&US0K];;6-'$Y$
M%^B-\T4@&5=&4DJV#C<'6@#^C6J]U=0V=N\]Q-';PH,M)(P51]2:X3XF?%2+
MP+\%];\?V-G)JZ66D-J=K91<M<L8]T2#&?O$J.*_%_PKX!^.O_!1/XYG3/&6
ML:EI<31RZ@\^J6DZ:?IL*L!M@@X7.7"J,Y/\3=30!^YMAXHT;5)?)LM6L+R;
M_GG;W*.WY FM:OQ)_:I_X)>:U^R[\);[XC:?\0H/$]GI,T'VR$Z8UA-$))4B
M1XR)I-Q$CIZ=<]J^C?\ @D-^TUXV^*$?B_P%XPU>Z\10:):07VFWU](TMS%&
MS&-X6E)+.N=A7.2OS#.-H !^E-5;[4+;2[=KB[N(K:!1\TDT@11^)K^>[_@H
MI_R>I\5/^PC%_P"DT5>J>*? /[2G_!2KQ%?^.].T:YD\$&[FCTB&^ODM-.M8
MT8J$B1V'F.,[6E53EMP+<;5 /V^M;J*]MTGMY5G@D4,DD; JP/<$=:LU^5G[
M>GA_Q7\$O^"??P.\-WEQ/H?B#2=0M;"]&GW9'SK9W&1O0_,,C-?-O[+J_M!_
MM,> ]<^$/P]UJ2UT8WAU77M9O[^6,&.2...&WDE 9PA\AR(T'S?-GA: /W0M
M/$6E:E=26MGJ5I=7*9W0PS*[KC@Y .:OR2);QL[L$C49+'@ "OYV?VA_V7_B
M5^Q9XN\/_P!OWMO:WE\KW.EZWX>O)=C-&0'"2%8Y$=-Z9^4??6O?O#>I?M+?
M\%./#]KX:L-7M+#POX7L;>UU.]OKF2UM-0NN<2SF.-VEF95R5"E4^]\N_P"8
M _9S3?$&EZTSC3]2M+XI]X6TR2;?KM)K2K^=+XY?L^_%+]A_XA:/'JVI+I.K
MSQ-=Z9KOAR]<*X0[6\N3:D@*Y7(('WEK]G/V+/VB+WXW_LIZ-X]\1D/J]G%<
MP:K)" /-DMV;,@48 +H%8CU;TQ0!]%R2);QL[L$C49+'@ "LRW\7:'>7"P0:
MSI\\YX$<=TC.3Z8!K\.O'7B?X\_\%!/CO8>&M135M T36+XQZ?I,\,\6F:;
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M_(<^#_\ U[:K_P"A6M?3G_!)G_DROPS_ -A'4/\ TI>OF/\ X+D?\ASX/_\
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M%K^?_ )>:.:.:.:^O/GC[)_X)T?>^(/TT_\ ]N:^T*^+_P#@G1][X@_33_\
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M/_I0M+^V;_P4)7]K;X0ZQX$^&'@KQ -#14U/Q#J>K01AX+6"1)%^2*2157S
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M_P#!%>-5_9?\5R8^8^,;I23UP+*RQ_.N1_X+??\ ).?AA_V%;O\ ]$I78?\
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M /,O'W[-OPK^*6JG4_%GP]\.:[J>,&^O=-B>=@,X#28W$<]":T_A[\$?A_\
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MC/85T/A_PWI7A+1[;2="TRRT72K5=EO8Z?;I!!$O7:B( JCV K6HH Y?QO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
'%%%% '__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
